Bah, A; (2019) A double blind randomised controlled trial comparing standard dose of iron supplementation for pregnant women with two screen-and-treat approaches using hepcidin as a biomarker for ready and safe to receive iron. PhD (research paper style) thesis, London School of Hygiene & Tropical Medicine. DOI: https://doi.org/10.17037/PUBS.04655033
Permanent Identifier
Use this Digital Object Identifier when citing or linking to this resource.
Abstract
WHO recommends daily iron supplementation (60mg) for all pregnant women where anaemia prevalence exceeds 40%. However, recent evidence suggests that iron supplementation may be harmful as it increases the risks of hypertension and of infection. Iron absorption is regulated by hepcidin, a key iron regulatory hormone with the potential to be a useful marker to determine if oral iron can be absorbed effectively and safely. We aimed to identify a hepcidin threshold to define ’safe and ready’ to receive iron and then test whether a hepcidin-guided screen-and-treat approach to iron supplementation is non-inferior to the WHO-recommended universal daily supplementation. Method: We established our screening threshold by measuring haemoglobin and serum hepcidin, ferritin, iron, soluble transferrin receptor (sTfR), and C-reactive protein (CRP) at 14, 20 and 30 week of gestation among 395 pregnant rural Gambian women using archived maternal blood samples (2010-2013), and analysed hepcidin’s diagnostic test accuracy [area under the receiver operating characteristic curve (AUCROC), sensitivity, specificity, cut offs] for iron deficiency at each time point. We established a threshold of 2.5μg/L. We then conducted a 3-arm randomised-controlled proof-of-concept trial in rural Gambia from June 2014 to March 2016. We recruited 498 pregnant women aged 18-45 years with 14-22 weeks gestation to receive either: (A) UNU/UNICEF/WHO international multiple micronutrient preparation (UNIMMAP) containing iron 60mg/d; (B) UNIMMAP containing iron 60mg/d but based on a weekly hepcidin screening <2.5μg/L indicating if iron can be given for the next 7 days or not; or (C): as in (B), but with iron 30mg/d. We report the per protocol analysis for primary and secondary outcomes at Day 84. We assessed non-inferiority with the primary endpoint being haemoglobin concentration at Day 84 with a non-inferiority margin of -5.0g/L. Results: The evidence for non-inferiority for screen-and-treat approaches using either 60mg iron (mean haemoglobin difference relative to Reference arm: -2.2g/L; 95% CI: -4.6, 0.1g/L) or 30mg iron (-2.7g/L; 95% CI: -5.0, -0.5g/L) was marginal. Anaemia (haemoglobin <110g/L) at the end of intervention was less prevalent in the Daily iron supplementation (Reference) arm than both Screen-and-treat arms. Among those without inflammation at the end of intervention, the prevalence of iron deficiency (ferritin <15ug/L) was less in the Reference arm compared to the two Screen-and-treat arms; corresponding prevalence values for transferrin saturation <16%; soluble transferrin receptor >4.4mg/L and hepcidin <2.5μg/L were lower in the Reference arm. The Screen-and-treat approaches had no added advantage than universal daily iron supplementation in terms of adherence, side effects or safety outcomes. Conclusion: The daily 60mg iron supplementation arm performed better than both screen-and-treat arms for anaemia and other iron markers (hepcidin, ferritin, soluble transferrin receptor, transferrin saturation). We therefore found no support for a screen-and-treat iron supplementation based on hepcidin concentration <2.5μg/L in pregnant Gambian women.
Item Type | Thesis |
---|---|
Thesis Type | Doctoral |
Thesis Name | PhD (research paper style) |
Contributors | Moore, SE and Prentice, AM |
Faculty and Department | Faculty of Epidemiology and Population Health > Dept of Population Health (2012- ) |
Research Group | Medical Research Council Unit, The Gambia at the London School of Hygiene & Tropical Medicine |
Funder Name | UK Medical Research Council (MRC) and the UK Department for International Development (DFID), under the MRC/DFID Concordat agreement to the MRC International Nutrition Group |
Grant number | MC-A760-5QX00 |
Copyright Holders | Amat Bah |
Download
Filename: 2019_EPH_PhD_Bah_A_FINAL.pdf
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 3.0
Download